Q4 beat and long-term guidance upgrade welcomed by the markets
06/02/25 -"The Q4 results exceeded the street’s expectations, while the 2025 outlook was in line with consensus estimates. Moreover, the firm raised its longer-term sales ambition, despite key HIV patent ..."
Pages
71
Language
English
Published on
06/02/25
You may also be interested by these reports :
17/03/25
Virbac’s 2024 operating profitability was somewhat ahead of the street’s expectations, backed by favourable prices, higher volumes and an improved ...
12/03/25
Roche and Zealand Pharma have agreed to co-develop and co-commercialise Zealand’s phase II weight-loss drug candidate, petrelintide, as monotherapy ...
11/03/25
Vague outlook and slight miss on topline might offer weakness to further build up a position
05/03/25
Worth building a position ahead of results at current price